Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IgPro20 (Hizentra) in post-COVID-19 POTS
2023-508744-22-00Phase 3Completed
- Sponsor
- CSL Behring
- Start
- May 2025
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in postural orthostatic tachycardia syndrome (POTS) comparing IgPro20 (Hizentra) with Placebo (2 arms). Primary endpoint: Proportion of participants no longer meeting diagnostic criteria of post-COVID POTS. Started May 2025; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
postural orthostatic tachycardia syndrome (POTS)
Beyond the preview
Go deeper on 2023-508744-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508744-22-00.